8-K: Cardiff Oncology Reports Positive Data and Financial Results for Q4 and Full Year 2024

Cardiff Oncology announced positive clinical data from its lead program in first-line RAS-mut mCRC, a successful $40 million financing, and a cash runway projected into Q1 2027.

Summary

• Cardiff Oncology reported financial results for the fourth quarter and full year ended December 31, 2024, along with a business update.
• The company highlighted positive initial data from its ongoing first-line RAS-mutated mCRC clinical trial (CRDF-004), showing a 64% objective response rate (ORR) in the 30mg onvansertib dose arm compared to 33% in the control arm.
• Cardiff Oncology completed an oversubscribed $40 million underwritten registered direct offering with participation from new and existing healthcare dedicated investors.
• A new patent was issued for the use of onvansertib in treating KRAS-mut mCRC, with claims covering the method of using onvansertib in combination with bev for bev-naive patients.
• As of December 31, 2024, the company had $91.7 million in cash and equivalents, projecting a cash runway into Q1 2027.
• Total operating expenses for the full year 2024 were approximately $49.3 million, an increase of $3.4 million from the previous year.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to promising clinical data, a successful financing, and a strong cash position. While there are risks inherent in drug development, the overall tone is optimistic.

Positives

• Positive initial data from the CRDF-004 trial shows promising efficacy of onvansertib in treating first-line RAS-mutated mCRC.
• The $40 million financing strengthens the company's balance sheet and supports ongoing clinical development.
• The new patent provides intellectual property protection for onvansertib's use in treating KRAS-mut mCRC.
• The company has a strong cash position of $91.7 million, providing a runway into Q1 2027.
• Onvansertib demonstrated synergy in combination with paclitaxel in hormone receptor positive (HR+) breast cancer cell lines and robust antitumor activity in patient-derived xenograft (PDX) models resistant to first-line therapies.
• A post hoc analysis revealed a greater clinical benefit in bev naive patients, who demonstrated an ORR of 77% and mPFS of 14.9 months compared to an ORR of 10% and mPFS of 6.6 months in those previously exposed to bev.

Negatives

• Net cash used in operating activities increased to $37.7 million for the full year 2024, compared to $30.9 million in 2023.
• Total operating expenses increased to $49.3 million for the full year 2024, compared to $45.9 million in 2023.
• The company reported a net loss of $45.4 million for the full year 2024, compared to a net loss of $41.4 million in 2023.

Risks

• Clinical trials are lengthy and expensive with uncertain outcomes.
• Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks.
• Results of preclinical studies or clinical trials could be unfavorable or delayed.
• The company may need additional financing in the future.
• The company faces risks related to business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks.
• There are uncertainties of government or third party payer reimbursement.
• The company depends on key personnel and faces substantial competition.
• There are uncertainties of patent protection and litigation.
• The company depends upon third parties.
• The company faces risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.

Future Outlook

The company expects to share additional clinical updates from the CRDF-004 trial in H1 2025.

Management Comments

• 2024 was a significant year for Cardiff Oncology as we shared positive data from the first 30 patients in our lead program in first-line RAS-mut mCRC, said Mark Erlander, Ph.D., Chief Executive Officer of Cardiff Oncology.
• We were excited to report that patients on the 30mg onvansertib dose arm demonstrated a 64% response rate, compared to a 33% response rate in the control arm.
• We believe this correlation between the dose of onvansertib and the magnitude of therapeutic effect serves as validation that onvansertib is a biologically active drug for the treatment of cancer, which we believe may translate to additional oncology indications in our pipeline.
• With our balance sheet strengthened by a $40M investment from biotech specialist investors, we now look forward to sharing additional clinical updates from CRDF-004 in H1 2025.

Industry Context

The announcement highlights Cardiff Oncology's progress in the competitive oncology space, particularly in developing therapies for RAS-mutated cancers, a significant unmet need. The company's focus on PLK1 inhibition and combination therapies aligns with current trends in cancer research and drug development.

Comparison to Industry Standards

• The 64% ORR in the 30mg onvansertib arm compares favorably to standard-of-care treatments for first-line RAS-mutated mCRC, which typically show response rates in the 30-40% range.
• Companies like Amgen (with Lumakras/Sotorasib) and Mirati Therapeutics (with Krazati/Adagrasib) are also targeting KRAS mutations, but Cardiff Oncology's approach focuses on PLK1 inhibition in combination with standard chemotherapy.
• The $40 million financing provides Cardiff Oncology with resources to advance its clinical programs, positioning it competitively against other biotech companies in the oncology space.

Stakeholder Impact

• Shareholders will likely react positively to the promising clinical data and strengthened financial position.
• Employees may be motivated by the company's progress and future prospects.
• Patients with RAS-mutated mCRC may benefit from the development of onvansertib as a new treatment option.
• Investors are likely to be interested in the company's progress and future clinical trial results.

Next Steps

• The company expects to share additional clinical updates from the CRDF-004 trial in H1 2025.

Key Dates